| Name | Title | Contact Details |
|---|
Establishment Labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. With more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for Establishment Labs` founders and top executives. As a result, Motiva Implants® has established a level of product innovation that always results in safety. And while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. We believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.
Safety Syringes, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Koya Medical is a transformative healthcare venture with a mission to treat cancer-related chronic lymphedema and venous diseases through innovative patient-centric platforms.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Cardiocom Multi-Disease Management is a Chanhassen, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.